[
    "{\"step_by_step_thinking\": \"Based on the information provided in the relevant documents, the safety and efficacy of Tilavonemab (ABBV-8E12) for the treatment of progressive supranuclear palsy (PSP) was assessed in a phase 2, multicentre, randomised, placebo-controlled, double-blind study. The study included 466 participants who were randomly assigned to receive Tilavonemab 2000 mg, Tilavonemab 4000 mg, or placebo. The primary endpoint was the change from baseline to week 52 in the Progressive Supranuclear Palsy Rating Scale (PSPRS) total score. The study was terminated after prespecified futility criteria were met, and the results showed that there was no significant difference in the change from baseline PSPRS total score between the Tilavonemab groups and the placebo group. Therefore, based on the available evidence, the answer is B. no.\", \"answer_choice\": \"B\"}"
]